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and Christopher I. Amos, PhD
Introduction: Three genome-wide association studies identified a
region on chromosome 15q25.1 associated with lung cancer and
measures of nicotine addiction. This region includes nicotinic ace-
tylcholine receptor subunit genes CHRNA3 and CHRNA5. These
studies were conducted in European or European American popu-
lations and do not provide risk estimates for African Americans. The
goal of this study was to determine whether recently identified
genetic variation in 3 SNPs (rs1051730, rs931794, rs8034191) on
chromosome 15q25.1 contributes to risk of lung cancer in African
Americans.
Methods: Data were derived from three case-control studies. Par-
ticipants included 1058 population-based non-small cell lung cancer
cases selected from the Detroit area SEER registry and 1314 con-
trols matched within study by age, race, and sex. Thirty-nine percent
of participants were African American.
Results: Risk associated with rs1051730 (odds ratio 1.59; 95%
confidence interval 1.16–2.19) and rs931794 (odds ratio 1.39; 95%
confidence interval 1.09–1.78) increased in ever smoking African
Americans adjusting for cigarettes smoked per day. Among white
cases, the number of cigarettes smoked varied by genotype at all
three SNPs, and when smoking quantity was included in the models,
risk was not significantly associated with any of the three SNPs.
Conclusions: These findings suggest that SNPs in the CHRNA3 and
CHRNA5 region contribute to lung cancer risk, and while variant
alleles are less frequent in African Americans, risk in this group may
be greater than in whites and less likely to reflect an indirect effect
on lung cancer risk through nicotine dependence.
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Lung cancer continues to be the leading cause of cancerdeath in the United States.1 Incidence rates are higher in
African Americans than in whites, with average annual age-
adjusted rates, 2001 to 2005, at 50.3 and 41.3 per 100,000,
respectively.1 With more than 85% of lung cancer risk attrib-
utable to cigarette smoking, this racial variation in incidence
occurs even though African Americans smoke fewer ciga-
rettes per day than whites.2 In addition, an understanding of
the influence of genetic susceptibility is not fully appreciated.
A genetic contribution to lung cancer risk has been suggested
by studies demonstrating familial aggregation of lung can-
cer.3 In addition, a study in high-risk lung-cancer families
reported linkage on chromosome 6q23–25 (146–164 cM) to
familial lung cancer;4 however, not all high-risk families have
been linked to this region and only about 1% of lung cancer
patients have such extensive family histories.
Running parallel to studies of rare genes, studies of
candidate genes have produced mixed results5 leaving open
the question of the contribution to risk from common, low-
penetrant genes. Alternative strategies to gene identification,
such as genome-wide association studies (GWAS), have
recently been completed to address this question. Three
GWAS, conducted in European and European American
populations, reported an association between non-small cell
lung cancer (NSCLC) risk and SNPs on 15q25.1.6–8 This
region has also been associated with familial lung cancer risk
in an additional genome-wide association study.9 The region
of interest contains nicotinic acetylcholine receptor subunit
genes CHRNA3 and CHRNA5, and one of the GWAS sup-
ports a stronger association with nicotine addiction than lung
cancer.8 Genetic variation in this region has also been linked
to smoking behavior,10 age-dependent nicotine addiction,11
and variability in internal dose of tobacco-specific nitro-
samine per cigarette.12
To further evaluate risk of lung cancer and smoking
behavior associated with this region, we genotyped three
SNPs on 15q25 in a pooled sample from three case-control
studies conducted in metropolitan Detroit. Each study iden-
tified population-based cases from the Metropolitan Detroit
Cancer Surveillance System, a participant in NCI’s SEER
program and included a relatively large sample of African
Americans.13–15
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MATERIALS AND METHODS
Institutional review board approval was obtained for all
studies, and informed consent was obtained from all partici-
pants. Table 1 describes the three studies included in the
analysis. All studies were conducted by the same study staff
using identical procedures, with cases ascertained through the
population-based Metropolitan Detroit Cancer Surveillance
System, an NCI-funded SEER registry. Studies differed only
in the eligibility of cases, with the family history study
focused on never smokers and cases diagnosed before the age
of 50 years. The women’s epidemiology of lung diseases
study focused on women, and the exploring health, ancestry,
and lung epidemiology (EXHALE) study focuses on African
Americans. The EXHALE study is an ongoing study. With
the exception of the EXHALE study, population-based con-
trols were chosen using random digit dialing methods. The
EXHALE study relies on volunteer controls identified
through research registries, advertisement, and word of
mouth. All study controls were frequency matched to cases
by 5-year age group, sex, and race. Questions about family
history and smoking history were obtained using the same
questionnaires in each study. The family history study case
interview response rate was 67.7%, and biospecimens, in-
cluding blood, buccal cells through buccal brush or mouth-
wash collection, and normal tissue from paraffin-embedded
tissue, were collected for 53.5% of these cases. The control
participation rate was 93.1% of those completing the eligi-
bility screeners, with 50.3% providing biospecimens. The
women’s epidemiology of lung diseases study had an inter-
view participation rate for cases of 54.2%, for controls of
69.6%, with biospecimens collected for 98.6% of subjects.
The EXHALE study is still recruiting and, to date, 87.3% of
subjects have provided a biospecimen. Volunteer controls
were selected for the EXHALE study that focuses on using
admixture mapping to identify novel genes for lung cancer. It
is unlikely that unknown genotype influences volunteer par-
ticipation or participation in any of the studies. Because 92%
of all cases had NSCLC, the results are restricted to 1058
NSCLC cases and 1314 controls providing a biospecimen.
Thirty-nine percent of the cases and 34% of the controls
included were African Americans.
DNA was isolated from blood using a Gentra AutoPure
Kit (Qiagen, Valencia, CA), buccal swabs with the Bucca-
lAmp DNA Extraction Kit (Epicenter Technologies, Madi-
son, WI), mouthwash samples with the Gentra Puregene Kit
(Qiagen), and paraffin-embedded tissue with the QIAamp
DNA Mini Kit (Qiagen) using standard protocols. TaqMan
Genotyping Assays (Applied Biosystems, Foster City, CA)
were used to detect polymorphisms in rs8034191, rs1051730,
and rs931794. DNA isolated from buccal cells or from
paraffin blocks was preamplified in an outer polymerase
chain reaction for added sensitivity. Either 25 ng DNA or 1
L of the outer nest was amplified, with primers designed
using Primer Express software (Applied Biosystems), and
detected using an AB 7900 Sequence Detection System
(Applied Biosystems). For quality control, 5% of the products
were sequenced and 10% were directly repeated.
Cases were compared with controls on demographic
factors using 2 tests for categorical variables and t tests for
continuous variables. Hardy-Weinberg equilibrium was as-
sessed using a 2 goodness-of-fit test for each SNP in African
American and white controls separately. Unconditional logis-
tic regression was used to examine the effect of these SNPs
on lung cancer risk, controlling for age, sex, and one of the
three measures of smoking behavior: ever smoking, pack-
years of smoking, or cigarettes smoked per day. Analyses
were conducted separately by race for whites and African
Americans. Results for models including pack-years and
cigarettes smoked per day were very similar; hence, the
unadjusted models and models including cigarettes per day
are presented. Participants of other races (26 cases and 26
controls) were excluded from the analysis. Analyses were
TABLE 1. Study Characteristics
Study Population Eligibility Criteria Years of Diagnosis
Ages of
Diagnosis (yr)
Control
Selection
Number of NSCLC
Cases Genotyped
Number of
Controls
Genotyped
Family history
study13,15,22
Never smokers  From November 1, 1984,
to June 30, 1987 
From September 15,
1990, to September 30,
2003
40–84  50 Random digit
dialing
299 570
Early onset with any
smoking history
Men and women
All races
All histologies
Women’s epidemiology
of lung disease14
All smoking histories From November 1, 2001
to October 31, 2005
74 Random digit
dialing
567 562
Only women
All races
Only NSCLC
Exploring health, ancestry
and lung epidemiology
All smoking histories From November 1, 2005,
to October 31, 2009
18–74 Volunteers 192 182
Men and women
Only African Americans
All histologies
Total NSCLC 1058 1314
NSCLC, non-small cell lung cancer.
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conducted assuming a log additive model. Analyses were
repeated stratified by smoking history, family history of lung
cancer in a first-degree relative, and age. A dominant model
was also tested for each SNP, with carriers of one or two
copies of the minor allele compared with carriers of two
major alleles, and results were very similar to those under the
log-additive model so these results are not presented. For
each SNP, a model including race and a race  genotype
interaction term was also created to evaluate the significance
of the difference between SNP associations by race. The asso-
ciation between mean cigarettes smoked per day and genotype
was evaluated using one-way analysis of variance within racial
group. Linkage disequilibrium (LD) between SNPs was deter-
mined using r2 values within each racial group. All statistics
were derived using SAS version 9.1 (SAS Institute, Cary, NC),
using the genetics module for analyses using SNPs.
RESULTS
All SNPs were in Hardy-Weinbnerg equilibrium (Table
2). Minor allele frequencies varied by race, with African
Americans less likely than whites to carry the minor alleles at
any of the three SNPs (Table 2). In a log-additive model, risk
of NSCLC associated with any of the SNPs among whites
was increased by 20–25%, when adjusting for age, sex, and
ever smoking (Table 3). However, after adjusting for ciga-
rettes smoked per day or pack-years, risk estimates in whites
were reduced and were no longer statistically significant.
Among African Americans, risk was not significantly asso-
ciated with rs8034191. In African Americans, significantly
increased risk was associated with rs931794 (odds ratio [OR]
1.41; 95% confidence interval [CI] 1.10–1.81) and rs1051730
(OR 1.66; 95% CI 1.20–2.30) after adjusting for age, sex, and
ever smoking. Risk remained unchanged and significantly
elevated among African Americans when adjustment was
made for cigarettes smoked per day for rs931794 and
rs1051730. None of the SNPs were associated with lung
cancer among never smokers (Table 4). In the subset of ever
smokers, ORs associated with risk of lung cancer were
1.18–1.36 in whites and 1.18–1.71 in African Americans
before adjusting for smoking amount. Risk estimates de-
creased and were no longer statistically significant in whites
after adjustment for cigarettes smoked per day, but similar
decreases in risk were not observed among African Ameri-
cans for rs931794 and rs1051730. In models including race,
race was a significant predictor of risk independent of geno-
type, and there was a significant interaction between race and
genotype for rs1051730 (p  0.04).
In a subset of cases with a family history of lung
cancer, all SNPs were associated with increased risk in whites
when cigarettes smoked per day was not included in the
model, and rs1051730 remained significant in whites with a
family history of lung cancer after adjusting for sex and
cigarettes smoked per day (OR 1.41; 95% CI 1.03–1.91;
Table 4). This SNP was also associated with lung cancer risk
among African Americans with a family history of lung
cancer (OR 1.83; 95% CI 1.10–3.06). In general, among
African Americans, family history did not greatly change
estimates of risk for any of the three SNPs. Risk varied by age
at lung cancer diagnosis in whites, with young onset disease
associated more strongly with these SNPs than in later onset
lung cancer, but again after adjustment for cigarettes per day
no significant increases in lung cancer risk were evident. In
African Americans, risk patterns were similar across age
groups, but statistically significant risks were only seen in
those 50 years of age or older. There were no significant
differences by sex (data not shown).
Because of possible associations between these SNPs
and nicotine dependence, we also evaluated whether mean
cigarettes smoked per day varied by genotype. White cases
carrying the variant allele at any of the three SNPs reported
significantly higher numbers of cigarettes smoked per day
than white cases carrying major alleles (Table 5). A similar
association was not seen in white controls. Cigarettes smoked
per day did not vary significantly by genotype in African
American cases or controls.
There is strong LD between all three SNPs in the popu-
lation of European ancestry in HapMap (Fig. 1A), and, in our
study population, r2 values in whites were more than 0.88
between any combination of the three SNPs. In a stepwise
TABLE 2. Study Participant Characteristics and Genotype
Frequencies by Race
White African American
Cases
(N  630)
Controls
(N  853)
Cases
(N  402)
Controls
(N  435)
Smoking status
Never smoked 111 (17.6) 451 (52.9) 41 (10.2) 196 (45.1)
Ever smoked 519 (82.4) 402 (47.1) 361 (89.8) 239 (54.9)
Family history of
lung cancer
No 491 (77.9) 763 (89.5) 322 (80.1) 380 (87.4)
Yes 139 (22.1) 90 (10.5) 79 (19.7) 55 (12.6)
Unknown 1 (0.2)
Age at diagnosis/
interview (yr)
50 211 (33.5) 411 (48.2) 121 (30.1) 149 (34.7)
50 419 (66.5) 442 (51.8) 281 (69.9) 286 (65.8)
rs8034191a
A/A 185 (34.3) 326 (40.3) 231 (64.2) 300 (71.3)
A/G 264 (49.0) 367 (45.4) 119 (33.1) 106 (25.2)
G/G 90 (16.7) 116 (14.3) 10 (2.8) 15 (3.6)
**p  0.43 **p  0.15
rs931794a
A/A 214 (34.6) 336 (40.3) 215 (54.4) 270 (62.9)
A/G 287 (46.4) 368 (44.2) 154 (39.0) 137 (31.9)
G/G 117 (18.9) 129 (15.5) 26 (6.6) 22 (5.1)
**p  0.09 **p  0.40
rs1051730a
G/G 207 (35.6) 344 (40.8) 279 (72.5) 353 (81.7)
A/G 280 (48.1) 379 (44.9) 96 (24.9) 74 (17.1)
A/A 95 (16.3) 121 (14.3) 10 (2.6) 5 (1.2)
**p  0.32 **p  0.62
a Genotype data were missing for 191 subjects for rs8034191, 45 subjects for
rs931794, and 77 subjects for rs1051730.
**p value for 2 test of Hardy-Weinberg Equilibrium in controls.
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logistic regression analysis in whites that did not include ciga-
rettes smoked per day, only rs931794 remained in the model as
significantly associated with lung cancer risk. However, once
smoking quantity was included, this SNP was not significantly
associated with lung cancer risk in whites. In the Yoruban
population in HapMap, there is little LD in this region (Fig. 1B).
In our population of African Americans, r2 values were 0.24 or
less between SNPs. When all three SNPs were included in a
logistic regression model in a stepwise fashion in African Amer-
icans, only rs1051730 was predictive of risk.
DISCUSSION
The frequency of genotypes in 15q25 SNPs, rs8034191,
rs931794, and rs1051730, in the white population was con-
sistent with reported frequencies in the GWAS studies.6–8
This is the first report on the frequency of these genotypes in
African Americans. Among African Americans, the homozy-
gous rare variant genotypes for each SNP were relatively
uncommon and occurred in fewer than 6% of the controls. A
recent study in Asians evaluated seven SNPs in this region
including rs8034191 and rs1051730.16 Allele frequencies in
Asians for these two SNPs were lower than what we observed
in whites and African Americans in our study; for rs8034191
the minor allele frequencies were reported to be 0.37, 0.16,
and 0.02 in whites, African Americans, and Asians, respec-
tively. Likewise, for rs1051730 the minor allele frequencies
were reported to be 0.37, 0.10, and 0.01 in whites, African
Americans and Asians, respectively.
Estimates of risk associated with these three SNPs are
consistent with the GWAS results6–8 and with the existence
of a gene associated with lung cancer, directly or indirectly
through nicotine dependence, on chromosome 15q25. Among
TABLE 3. Risk Estimates for NSCLC for Chromosome 15q25 SNPs by Race
SNP
White African American
ORa (95% CI) ORb (95% CI) ORa (95% CI) ORb (95% CI)
rs8034191 1.25 (1.04–1.49) 1.10 (0.91–1.33) 1.17 (0.88–1.57) 1.17 (0.88–1.56)
rs931794 1.25 (1.06–1.46) 1.13 (0.96–1.34) 1.41 (1.10–1.81) 1.39 (1.09–1.78)
rs1051730 1.20 (1.01–1.42) 1.07 (0.90–1.28) 1.66 (1.20–2.30) 1.59 (1.16–2.19)
a Log additive model adjusted for age at diagnosis/interview, sex, and smoking status (ever/never).
b Log additive model adjusted for age at diagnosis/interview, sex, and cigarettes smoked per day.
OR, odds ratio; CI, confidence interval.
TABLE 4. Estimates of NSCLC Risk Associated With SNPs on 15q25 by Race, Smoking History, Family History, and Age at
Diagnosis/Interview
Subject Characteristics
rs8034191 rs931794 rs1051730
ORa (95% CI) ORb (95% CI) ORa (95% CI) ORb (95% CI) ORa (95% CI) ORb (95% CI)
Smoking history
Whites
Never smokers 0.94 (0.61–1.43) 0.94 (0.61–1.43) 1.01 (0.75–1.37) 1.01 (0.75–1.37) 0.90 (0.63–1.28) 0.90 (0.63–1.28)
Ever smokers 1.32 (1.08–1.61) 1.18 (0.95–1.46) 1.36 (1.12–1.65) 1.21 (0.98–1.49) 1.31 (1.07–1.59) 1.21 (0.98–1.49)
African Americans
Never smokers 1.03 (0.44–2.43) 1.03 (0.44–2.43) 1.06 (0.61–1.84) 1.06 (0.61–1.84) 1.47 (0.70–3.06) 1.47 (0.70–3.06)
Ever smokers 1.20 (0.88–1.63) 1.18 (0.86–1.61) 1.54 (1.15–2.05) 1.54 (1.15–2.06) 1.71 (1.18–2.48) 1.67 (1.15–2.43)
Family history of lung cancer
Whites
No 1.19 (0.99–1.44) 1.05 (0.86–1.29) 1.20 (1.01–1.42) 1.10 (0.92–1.32) 1.11 (0.93–1.33) 1.00 (0.82–1.21)
Yes 1.43 (1.07–1.89) 1.30 (0.96–1.78) 1.43 (1.09–1.86) 1.31 (0.98–1.75) 1.55 (1.17–2.06) 1.41 (1.03–1.91)
African Americans
No 1.17 (0.87–1.59) 1.15 (0.85–1.56) 1.42 (1.09–1.85) 1.40 (1.07–1.82) 1.59 (1.13–2.24) 1.54 (1.09–2.16)
Yes 1.16 (0.73–1.85) 1.29 (0.81–2.05) 1.35 (0.89–2.05) 1.39 (0.93–2.11) 1.80 (1.07–3.05) 1.83 (1.10–3.06)
Age at diagnosis/interview (yr)
Whites
50 1.37 (1.04–1.80) 1.27 (0.95–1.69) 1.35 (1.04–1.75) 1.23 (0.94–1.60) 1.36 (1.04–1.77) 1.25 (0.95–1.65)
50 1.14 (0.90–1.45) 0.97 (0.75–1.25) 1.17 (0.95–1.44) 1.06 (0.86–1.33) 1.06 (0.85–1.33) 0.93 (0.73–1.19)
African Americans
50 1.53 (0.91–2.57) 1.36 (0.81–2.28) 1.32 (0.85–2.05) 1.21 (0.78–1.90) 1.83 (1.04–3.22) 1.68 (0.95–2.96)
50 1.05 (0.74–1.50) 1.12 (0.79–1.59) 1.46 (1.07–1.99) 1.48 (1.09–1.99) 1.56 (1.04–2.33) 1.52 (1.03–2.25)
a Log additive model adjusted for age at diagnosis/interview, sex and smoking status (ever/never).
b Log additive model adjusted for age at diagnosis/interview, sex and cigarettes smoked per day.
OR, odds ratio; CI, confidence interval.
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white cases in our studies, all three SNPs were significantly
related to smoking amount measured as cigarettes smoked per
day and may contribute to lung cancer risk through increased
exposure to tobacco smoke. Risk associated with these SNPs
is highest in ever smoking whites after adjustment for ciga-
rettes per day for rs931794, but these findings did not reach
statistical significance. Amos et al.6 also report weak evi-
dence of a relationship between genotype and smoking be-
havior and there is extensive literature indicating that SNPs in
this region associate with smoking behavior8,17. It is possible
that this study was underpowered to detect a small increase in
lung cancer risk, on the order of 10–15%, independent of
smoking quantity in whites.
The effect of smoking amount is not evident among
African Americans, where the increased lung cancer risk
associated with two of the three SNPs was independent of
smoking dose. Results were most significant in African
Americans for rs1051730, which is in a LD block encom-
passing CHRNA3/CHRNA5. Although variant alleles were
less frequent in African Americans, risk in this group was
similar if not greater than that in whites. Reasons underlying
the racial difference in the genotype/smoking amount asso-
ciations are unknown. It is possible that cigarettes per day do
not adequately measure nicotine dependence in African
Americans. It is also possible that a marker linked to the
SNPs studied is the causal variant, and the frequency of that
marker and its association with number of cigarettes smoked
varies by race.
In this study population, no increased risk of lung
cancer was associated with these SNPs among never smok-
ers. Similar results were shown in one of the replication
studies presented by Amos et al.6 and an additional replica-
tion population from Texas,18 but in the study of Hung et al.7
lung cancer in never smokers was associated with rs8034191
genotype. In the study conducted in Japan, a haplotype
including rs8034191 and rs1051730 in combination with
rs16969968 was associated with lung cancer risk both in
smokers and non-smokers.16 The numbers of never smokers
with lung cancer included in any of these studies are rela-
tively small and this is an area that deserves more attention in
future studies.
Liu et al.9 report higher risks associated with 15q
polymorphisms for familial lung cancer. In that small study,
risks were increased more than threefold among homozygous
carriers of the rare alleles. In this study, the only significant
finding of risk among whites, after adjusting for cigarettes per
day, was for rs1051730 in those with a family history of lung
cancer. A stronger association at this SNP was seen for
African Americans with a family history, but risk associated
with these SNPs, in general, did not vary greatly between
African Americans with and without a family history of lung
cancer. Liu et al. included individuals with three or more
family members affected, whereas in our study, most subjects
with a family history had only one affected relative.
In addition to the myriad of carcinogens present in
tobacco smoke, nicotine and the nicotinic acetylcholine re-
ceptor pathway may be involved in the pathogenesis of lung
cancer through inhibition of proapoptotic pathways and pro-
motion of cell proliferation, invasion, and angiogenesis.19–21
Candidate genes in this 15q region include CHRNA3 and
CHRNA5. The strong link between smoking amount and lung
cancer makes it difficult to determine whether lung cancer
risk is more directly associated with variation in this genetic
region or indirectly through increased exposure because of
nicotine addiction. Three of the four GWAS studies and this
study did not include measures of nicotine dependence other
than smoking dose and duration making nicotine addiction
difficult to classify. SNPs in this region have been associated
with nicotine dependence severity among subjects initiating
daily smoking at or before age 16 years11 and heavy smok-
ing.10 These studies were conducted in healthy populations
and included only whites. Most recently, Le Marchand et al.12
demonstrated that variants in CHRNA3 (rs1051730, and in-
cluded in this study) and CHRNA5 (rs16969968, which is in
near perfect LD with rs1051730 in whites) alter internal dose
of a carcinogenic tobacco-specific nitrosamine per cigarette
smoked, as measured in urine. Although that study included
small numbers of African Americans, results were not pre-
sented by race. Taken together, reported findings suggest that
more sensitive markers of smoking dose are needed to fully
understand the genetics underlying nicotine dependence and
lung cancer.
The study presented here has a number of strengths
including population-based case selection. It is the first report
of the role of SNPs on 15q24–25 in lung cancer and smoking
behavior in African Americans. There are also some limita-
tions to this study. Response rates for population-based lung
cancer case-control studies, in general and in our studies, tend
to be low because of the poor survival and great morbidity
associated with this disease. However, genotype at any of the
TABLE 5. Mean Number of Cigarettes Smoked Per Day by
Genotype and Race Among Ever Smoking Cases and
Controls
SNPs
Mean Cigarettes/day
White African American
Controls
(N  397)
Cases
(N  517)
Controls
(N  238)
Cases
(N  359)
rs8034191
A/A 17.4 25.0 15.2 18.1
A/G 19.0 28.1 15.1 20.6
G/G 18.0 29.2 11.9 18.9
pa 0.42 0.02 0.67 0.15
rs931794
A/A 17.1 24.9 15.1 19.4
A/G 18.8 28.3 15.4 18.7
G/G 17.7 29.3 10.1 22.0
pa 0.33 0.009 0.33 0.43
rs1051730
G/G 17.1 25.4 15.0 18.5
A/G 18.9 28.3 15.4 20.2
A/A 18.5 29.4 5.7 22.5
pa 0.27 0.03 0.35 0.30
a One-way ANOVA.
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FIGURE 1. A, LD structure at 15q25 in individuals of European ancestry. Boxes are shaded according to r2 values derived in
Haploview (v3.2). Triangular border areas denote haplotype blocks assigned according to the method of Gabriel et al.23 B, LD
structure at 15q25 in Yorubans. Boxes are shaded according to r2 values derived in Haploview (v3.2). Triangular border areas
denote haplotype blocks assigned according to the method of Gabriel et al.23
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three SNPs was not associated with survival, so survival bias
is not likely to account for the results presented. In addition,
the only measures of nicotine dependence available were
smoking dose and duration.
As the first of the GWAS results are being published, it
is reassuring that four GWAS in lung cancer identified the
same region and that there are biologically plausible genes in
this region. What is more daunting is how best to use the data
coming from these studies. GWAS data are analyzed as if
SNPs are independent, and there is little evaluation of gene-
gene or gene-environment interactions. Because of genetic
variation, GWAS are typically conducted in European or
European American populations. Replication of findings in
other populations with different LD patterns and in this case,
different smoking patterns, may provide important clues in
attempts to fine map regions of interest. Further identification
of the specific genetic changes associated with NSCLC and
nicotine dependence should include the study of African
Americans who have higher rates of lung cancer than whites,
but have different patterns of cigarette use.
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